Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing

Set Alert for Manufacturing

German Funds Deny Tenders Link To Shortages

Leaked political proposals to stop German insurance funds awarding tender contracts to just one supplier would not help to prevent drug shortages, insists the leading AOK group of funds.

Germany Generic Drugs

India's USV Reveals Investment Plans

Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.

Manufacturing Strategy

The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy

Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.

Manufacturing Regulation

Nitrosamine Issue Presages Paradigm Shift In Quality

The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.

Manufacturing Regulation

Mylan Will Invest $1bn In India

Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.

Strategy Manufacturing

Teligent Weighs Sales Of Non-Core Assets

US topicals, ophthalmics and injectables generics player Teligent has asked an investment bank to help it explore selling off non-core assets. The New Jersey-based firm wants funds to help capitalize on its newly built injectables facility.

Business Strategies North America
See All
UsernamePublicRestriction

Register

Advertisement